undamentalytics Newsletter
Sign in

Maravai Lifesciences Holdings, Inc. (MRVI) stock

Add to watchlist

Add holding +

NASDAQ: MRVI Nasdaq Life Sciences Tools & Services Next results ~November 4, 2026

C Fundamentals grade

Maravai Lifesciences Holdings, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$4.5

Forward price-to-sales vs peers

Base case. Range ~$3.7–$11. Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Maravai Lifesciences Holdings, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 1 selling5 purchases and 2 sales by directors and officers, last 12 monthsInsider trades
  • Funds98 adding, 76 cuttingOf 39 active managers that changed their stake, 29 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Maravai Lifesciences Holdings files

Where Maravai Lifesciences stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $209m, down 5.0% on a year earlier, a smaller fall than the 15.4% decline a quarter earlier. That puts it 31 of 31 for growth among the life sciences tools & services companies we cover. Free-cash-flow margin rose to -17.2% from -19.5% a year earlier. Operating margin widened to -56.1% from -145.0%. The diluted share count is up 2.3% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 7 financial-health checks. Our price-to-sales vs peers value is $4.95 a share, against a share price of $8.40.

Source: 10-Q filed August 7, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Maravai Lifesciences Holdings, Inc.'s trailing-twelve-month revenue fell 5.0% year on year, with a free-cash-flow margin of -17.2%. Where it stands out: change in growth rate of +10.3pp ranks 6 of 54 life sciences tools & services companies we cover. Where it lags: revenue growth of -5.0% ranks 48 of 54 life sciences tools & services companies we cover.

Current signal Net income rising while operating cash flow falls: TTM net income grew 59.8% while operating cash flow fell 19.4% — earnings and cash are telling different stories.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 88.9 points on a year ago.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 5.0% over the last 12 months.
  • Loss-making. Operating margin is -56.1%: costs exceed revenue.
  • Burning cash. Free cash flow was -17.2% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 2.3% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 70% and a beta of 1.6 against the S&P 500.

Latest results: FY2026 Q2

Filed August 7, 2026
Earnings per share
-$0.02 against an average estimate of -$0.04: beat by 54.5%
Revenue
$51m, up 8.5% on a year earlier
Share reaction
-2.8% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Guidance given
revenue $205m to $215m (full year 2026); adjusted EBITDA (non-GAAP) $33m to $35m (full year 2026)
Next report
November 4, 2026; average EPS estimate -$0.06

Maravai Lifesciences Holdings' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+4.2%
  • 1 week-9.3%
  • 1 month-5.1%
  • This year+121.2%
  • 1 year+154.9%
  • 5 years-83.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$209M
Operating margin
-56.1%
Net margin
-37.1%
EPS (TTM, diluted)
$-0.53

Growth

Revenue growth
−5.0%
Change in growth rate
+10.3 pts
Share count change
+2.3%

Cash

Free cash flow (TTM)
-$35.8M
FCF margin
-17.2%
Stock pay % of revenue
14.3%

Earnings

Last results
August 6, 2026
Next results (est.)
November 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Guidance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Maravai Lifesciences Holdings, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Maravai Lifesciences Holdings, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.98 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$4.5 ~$3.7–$11 Included, half weight
Cash-flow model (DCF) Free cash flow after stock pay, grown then faded to 2.5%, discounted at 8.5%. — Does not apply: Noncontrolling ownership is material. Its fair value and share of cash flow must be valued separately; a book-value deduction is insufficient.
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: Noncontrolling ownership is material. Its fair value and share of cash flow must be valued separately; a book-value deduction is insufficient.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: Noncontrolling ownership is material. Its fair value and share of cash flow must be valued separately; a book-value deduction is insufficient.
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$4.5 ~$3.7–$11 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Maravai Lifesciences Holdings, Inc. with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202020212022202320242025Now
Share price$28.05$41.90$14.31$6.55$5.45$3.25$7.19
Market value$405m$5.4bn$1.8bn$864m$752m$469m$1.1bn
+ Net debt (− = net cash)$314m−$7m−$94m−$42m−$23m$77m$80m
Enterprise value$719m$5.4bn$1.7bn$822m$729m$547m$1.1bn
Multiples
Price / sales 1.4x6.8x2.1x3.0x2.9x2.5x5.0x
Price / earnings 4.6x29.7x8.3x————
Price / free cash flow 3.2x15.3x3.5x14.2x———
EV / EBITDA 5.7x9.6x3.0x————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

23 /100

Weak moat

How hard Maravai Lifesciences Holdings's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -9.3% of total assets over 5 years.

  • Durability 2 / 20

    Operating margin has been a median 10.0%; its worst year was -145.0%.

  • Cash conversion 15 / 20

    Free cash flow was positive in 3 of 6 years, at a median 21.6% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (28 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $44m and EPS of −$0.06 (range −$0.08 to −$0.04) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.11 +63% $212m +14%
Next −$0.10 +6% $225m +6%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −5.4% on 90 days ago. In the last 30 days, 6 analysts raised Maravai Lifesciences Holdings, Inc.'s forecast and 2 cut it.

Consensus EPS forecast Maravai Lifesciences Holdings, Inc., last 90 days
−$0.20 −$0.15 −$0.10 −$0.05 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.11 Current fiscal year, 60 days ago: −$0.18 Current fiscal year, 30 days ago: −$0.18 Current fiscal year, 7 days ago: −$0.11 Current fiscal year, Now: −$0.11 −$0.11 Next fiscal year, 90 days ago: −$0.09 Next fiscal year, 60 days ago: −$0.10 Next fiscal year, 30 days ago: −$0.11 Next fiscal year, 7 days ago: −$0.10 Next fiscal year, Now: −$0.10 −$0.10

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.11−$0.09
60 days ago −$0.18−$0.10
30 days ago −$0.18−$0.11
7 days ago −$0.11−$0.10
Now −$0.11−$0.10

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.04 −$0.02 +54.5%
Mar 2026 −$0.05 $0.01 +121.0%
Dec 2025 −$0.07 −$0.04 +43.0%
Sept 2025 −$0.08 −$0.08 +2.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 6, 2026
  • Revenue full year 2026 $205m to $215m Maintained
    “Revenue for the full year 2026 is expected to be in the range of $205.0 million to $215.0 million.” source
  • Adjusted EBITDA (non-GAAP) full year 2026 $33m to $35m Non-GAAP Raised
    “Adjusted EBITDA (non-GAAP) is now expected to be in the range of $33.0 million to $35.0 million, up from the prior range of $30.0 million to $32.0 million.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

9 analysts, Oct 2026
Buy556%
Hold444%
Sell00%

Monthly trend

  1. Oct 2026549
  2. Sep 2026448
  3. Aug 2026538
  4. Jul 2026538

Counts of recommendations published by analysts covering Maravai Lifesciences Holdings, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
10.6%
of tradable shares
Days to cover
4.94
at average volume
Short interest, 1 month
+8%
to October 15, 2026
Held by institutions
99%
of shares
Held by insiders
7.2%
of shares
Employees
415
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +129.0%

$3.14 on October 31, 2025 to $7.19

ThenNowEffect
Revenue (last 12 months) $220m $209m −5.0%
P/S multiple 2.0x 5.0x +146.6%
Share count 143m 146m −2.2%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +4.2%

$6.90 on November 3, 2023 to $7.19

ThenNowEffect
Revenue (last 12 months) $544m $209m −61.6%
P/S multiple 1.7x 5.0x +203.3%
Share count 131m 146m −10.5%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
MRVI+49%−66%−54%−17%−40%+121%
Industry peers (median)+4%−51%−3%−13%−2%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
MRVI58%25%25%33%50%82%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
MRVI−42%−70%−72%−61%−72%−30%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 20, 2020: 97% from August 20, 2021 to April 16, 2025. Getting back needed a 3424% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.83 – $9.00
From 52-week high
−20.1%
vs 50-day average
−3.7%
vs 200-day average
+36.9%
Volatility (1 year)
70%
Beta vs S&P 500
1.56

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±13.9%
After a week
6 up, 6 down
typical move ±18.1%
After a month
5 up, 7 down
typical move ±20.3%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 −2.8% +0.5% −9.8% +14.2%
May 7, 2026 +23.1% +0.5% +8.9% +27.9%
February 25, 2026 +14.1% +0.3% +22.4% −1.0%
November 6, 2025 0.0% −1.0% +13.2% +25.8%
August 11, 2025 +22.3% +0.9% +16.8% +18.2%
May 12, 2025 +4.0% +4.0% +9.6% +15.2%
March 18, 2025 −8.0% 0.0% −12.9% −34.8%
February 25, 2025 −19.0% −0.4% −29.2% −40.9%
January 8, 2025 −19.8% −1.4% −24.5% −28.9%
November 7, 2024 −36.8% +1.2% −35.2% −32.4%
August 7, 2024 −6.8% +1.6% −9.6% −0.4%
May 8, 2024 +10.0% +0.6% +25.0% −3.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Maravai Lifesciences Holdings, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Maravai Lifesciences Holdings, Inc.
$100M $200M $300M $400M $500M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $419.5M Revenue (TTM), FY23 Q4: $288.9M Revenue (TTM), FY24 Q1: $274.1M Revenue (TTM), FY24 Q2: $274.6M Revenue (TTM), FY24 Q3: $276.8M Revenue (TTM), FY24 Q4: $259.2M Revenue (TTM), FY25 Q1: $241.9M Revenue (TTM), FY25 Q2: $219.8M Revenue (TTM), FY25 Q3: $192.4M Revenue (TTM), FY25 Q4: $185.7M Revenue (TTM), FY26 Q1: $204.7M Revenue (TTM), FY26 Q2: $208.8M $208.8M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $419.5M
FY23 Q4 $288.9M
FY24 Q1 $274.1M
FY24 Q2 $274.6M
FY24 Q3 $276.8M
FY24 Q4 $259.2M
FY25 Q1 $241.9M
FY25 Q2 $219.8M
FY25 Q3 $192.4M
FY25 Q4 $185.7M
FY26 Q1 $204.7M
FY26 Q2 $208.8M
Revenue growth, TTM YoY Maravai Lifesciences Holdings, Inc.
-80% -60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -53.7% Revenue growth, TTM YoY, FY23 Q4: -67.3% Revenue growth, TTM YoY, FY24 Q1: -61.8% Revenue growth, TTM YoY, FY24 Q2: -49.5% Revenue growth, TTM YoY, FY24 Q3: -34.0% Revenue growth, TTM YoY, FY24 Q4: -10.3% Revenue growth, TTM YoY, FY25 Q1: -11.8% Revenue growth, TTM YoY, FY25 Q2: -19.9% Revenue growth, TTM YoY, FY25 Q3: -30.5% Revenue growth, TTM YoY, FY25 Q4: -28.3% Revenue growth, TTM YoY, FY26 Q1: -15.4% Revenue growth, TTM YoY, FY26 Q2: -5.0% -5.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -53.7%
FY23 Q4 -67.3%
FY24 Q1 -61.8%
FY24 Q2 -49.5%
FY24 Q3 -34.0%
FY24 Q4 -10.3%
FY25 Q1 -11.8%
FY25 Q2 -19.9%
FY25 Q3 -30.5%
FY25 Q4 -28.3%
FY26 Q1 -15.4%
FY26 Q2 -5.0%
Operating margin (TTM) Maravai Lifesciences Holdings, Inc.
-150% -100% -50% 0% 50% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 20.2% Operating margin (TTM), FY23 Q4: -11.0% Operating margin (TTM), FY24 Q1: -19.4% Operating margin (TTM), FY24 Q2: -20.0% Operating margin (TTM), FY24 Q3: -74.1% Operating margin (TTM), FY24 Q4: -90.9% Operating margin (TTM), FY25 Q1: -109.9% Operating margin (TTM), FY25 Q2: -145.0% Operating margin (TTM), FY25 Q3: -100.9% Operating margin (TTM), FY25 Q4: -115.9% Operating margin (TTM), FY26 Q1: -82.2% Operating margin (TTM), FY26 Q2: -56.1% -56.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 20.2%
FY23 Q4 -11.0%
FY24 Q1 -19.4%
FY24 Q2 -20.0%
FY24 Q3 -74.1%
FY24 Q4 -90.9%
FY25 Q1 -109.9%
FY25 Q2 -145.0%
FY25 Q3 -100.9%
FY25 Q4 -115.9%
FY26 Q1 -82.2%
FY26 Q2 -56.1%
FCF margin (TTM) Maravai Lifesciences Holdings, Inc.
-40% -20% 0% 20% 40% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 38.8% FCF margin (TTM), FY23 Q4: 21.0% FCF margin (TTM), FY24 Q1: -11.2% FCF margin (TTM), FY24 Q2: -6.2% FCF margin (TTM), FY24 Q3: -3.9% FCF margin (TTM), FY24 Q4: -8.6% FCF margin (TTM), FY25 Q1: -9.1% FCF margin (TTM), FY25 Q2: -19.5% FCF margin (TTM), FY25 Q3: -34.5% FCF margin (TTM), FY25 Q4: -38.1% FCF margin (TTM), FY26 Q1: -25.7% FCF margin (TTM), FY26 Q2: -17.2% -17.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 38.8%
FY23 Q4 21.0%
FY24 Q1 -11.2%
FY24 Q2 -6.2%
FY24 Q3 -3.9%
FY24 Q4 -8.6%
FY25 Q1 -9.1%
FY25 Q2 -19.5%
FY25 Q3 -34.5%
FY25 Q4 -38.1%
FY26 Q1 -25.7%
FY26 Q2 -17.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 143 284 799 883 289 259 186 209
Gross profit 76 204 659 714 140 108 34 73
EBITDA 28 125 561 582 −19 −215 −192 −95
Operating income 24 120 555 574 −32 −236 −215 −117
Net income −4 89 182 220 −119 −145 −131 −77
Diluted EPS −$0.06 $4.72 $3.12 $3.34 −$0.90 −$1.05 −$0.90 −$0.53
Growth (year on year)
Revenue — +98.5% +181.3% +10.5% −67.3% −10.3% −28.3% −5.0%
EBITDA — +351.5% +347.1% +3.7% −103.2% — — —
Operating income — +399.8% +362.6% +3.5% −105.5% — — —
Net income — — +104.6% +21.0% −154.1% — — —
Diluted EPS — — −33.9% +7.1% −126.9% — — —
Margins
Gross margin 53.3% 72.0% 82.4% 80.9% 48.5% 41.8% 18.3% 34.9%
EBITDA margin 19.4% 44.2% 70.2% 65.9% −6.5% −82.9% −103.2% −45.5%
Operating margin 16.8% 42.2% 69.4% 65.0% −11.0% −90.9% −115.9% −56.1%
Net margin −3.1% 31.3% 22.8% 24.9% −41.2% −55.9% −70.4% −37.1%
Free-cash-flow margin 4.9% 44.6% 44.3% 58.8% 21.0% −8.6% −38.1% −17.2%
Cash flow
Cash from operations 24 152 369 536 126 7 −58 −25
Capital spending 17 25 15 17 66 30 13 11
Free cash flow 7 127 354 519 61 −22 −71 −36
Stock-based pay 2 25 10 19 35 49 30 30
Free cash flow after stock pay 5 102 343 500 26 −72 −101 −66
Balance sheet
Cash 25 236 551 632 575 322 217 70
Total debt 0 550 544 539 533 300 294 150
Net debt (negative = net cash) −25 314 −7 −94 −42 −23 77 80
Diluted shares 127m 14m 129m 128m 132m 138m 144m 146m
Returned to shareholders
Buybacks 0 34 0 0 — — — —
Total returned 0 34 0 0 — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 7 checks passed · June 30, 2026
What it owns · $604m
Short-term assets $156mLonger-term assets $448m
What it owes, and who funded it · $453m
Short-term liabilities $38mLonger-term liabilities $210mShareholders' equity $205m
  • Short-term assets cover short-term liabilities $156m of assets due within a year against $38m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $156m short-term assets against $210m of longer-dated liabilities.
  • More cash than debt $70m of cash against $147m of debt.
  • Debt below 40% of shareholders' equity Debt is 72% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 166% to 72% over five years.
  • A year's operating cash flow covers at least 20% of debt −$25m of operating cash flow against $147m of debt.
  • Operating profit covers interest at least five times over Operating income of −$117m against $24m of interest.

From Maravai Lifesciences Holdings, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+2.3%
year over year
R&D spending
7.3%
of revenue
Sales & admin spending
61.4%
of revenue
Days sales outstanding
54 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated MRVI CTKB CYRX MLAB SDGR GRAL Median
Revenue, last 12 months $209m $207m $186m $250m $259m $165m $229m
Revenue growth, last 12 months −5.0% 5.4% 12.1% 3.0% 8.9% 23.1% 6.9%
Revenue growth, 3-year average −27.3% 5.6% −8.2% 4.4% 10.2% — 2.9%
Revenue growth, latest quarter 8.5% 5.6% 7.7% 1.0% 7.5% 25.7% 8.5%
Gross margin 34.9% 53.2% 47.1% 64.2% 56.9% — 51.9%
Operating margin −56.1% −21.6% −21.2% 9.0% −59.2% −338.4% −14.3%
Operating margin, 3-year average −73.7% −16.1% −60.1% −34.7% −81.0% <−999% −22.4%
Net margin −37.1% −39.0% −20.1% 1.9% −21.0% −236.9% −16.1%
Cash from operations / revenue −12.1% −2.9% 4.3% 22.3% −49.0% −178.4% 1.3%
Free-cash-flow margin −17.2% −5.9% −10.8% 21.2% −50.3% −179.2% −2.2%
Free-cash-flow margin, 3-year average −14.3% 1.7% −22.6% 17.9% −45.4% — 0.6%
Stock pay / revenue 14.3% 10.3% 5.2% 6.5% 14.9% 38.9% 4.4%
Change in share count 2.3% −0.3% 0.6% 3.0% 1.7% 18.5% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth -5.0% 6.9% 48 of 54
Change in growth rate Growth +10.3pp +0.4pp 6 of 54
Gross margin Profitability 34.9% 52.0% 36 of 45
Operating margin Profitability -56.1% -14.3% 36 of 52
Net margin Profitability -37.1% -12.2% 36 of 54
Free-cash-flow margin Cash generation -17.2% -1.3% 37 of 54
Stock pay as % of revenue Cash generation 14.3% 4.4% 40 of 53
Long-term debt as % of assets Balance sheet 24.2% 26.3% 15 of 35
Change in share count Balance sheet 2.3% 1.0% 28 of 46
Days sales outstanding Balance sheet 54 days 62 days 18 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Tri Link $120M 64.5% ▼ 39.0%
Cygnus $66M 35.5% ▲ 5.0%
Geography
Region Revenue Share YoY
North America $112M 60.8% ▼ 11.6%
United States $111M 98.7% ▼ 10.3%
Latin and Central America $971,000 0.9% ▲ 46.7%
Asia Pacific $41.5M 22.4% ▼ 53.6%
EMEA $30.9M 16.7% ▼ 26.5%

From Maravai Lifesciences Holdings, Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$898M
Institutions reporting
177
Shares held vs prior quarter
▲ 18.5%
Positions opened / closed
41 / 23

Top buyers and sellers, Q2 2026: 98 institutions bought and 76 sold ; the biggest buyer was Millennium Management LLC (+4.9M shares) and the biggest seller Mackenzie Financial Corp (−6.3M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Gtcr LLC $126M 20.2M 14.0% 0.0%
Blackrock, Inc. $62.2M 10.0M 6.9% ▲ 6.7%
Braidwell LP $54.3M 8.7M 6.1% ▼ 15.0%
First Eagle Investment Management, LLC $45.8M 7.3M 5.1% ▲ 190.9%
12 West Capital Management LP $44.1M 7.1M 4.9% ▼ 2.8%
Millennium Management LLC $40.6M 6.5M 4.5% ▲ 294.6%
Vanguard Capital Management LLC $33M 5.3M 3.7% ▼ 3.0%
Ophir Asset Management Pty Ltd $30.1M 4.8M 3.4% New
Renaissance Technologies LLC $28.7M 4.6M 3.2% ▲ 8.0%
Deutsche Bank Ag\ $26.9M 4.3M 3.0% ▲ 401.6%
Geode Capital Management, LLC $19.5M 3.1M 2.2% ▲ 10.7%
State Street Corp $18.1M 2.9M 2.0% ▲ 19.5%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Maravai Lifesciences Holdings, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $1.9M 5 trades by 2 insiders, last 12 months Insider sales History → $254,000 2 trades by 1 insider · 100% under pre-set plans
Net ▲ $1.6M net buying
Insider Date Trade Shares Price Value
Oreshack Kurt General Counsel June 10, 2026 Sell pre-set plan 25,000 $5.10 $127,500
Oreshack Kurt General Counsel June 9, 2026 Sell pre-set plan 25,000 $5.06 $126,500
Lucier Gregory T Director December 8, 2025 Buy 48,528 $3.67 $178,098
Lucier Gregory T Director December 5, 2025 Buy 51,472 $3.70 $190,446
Brust Bernd Chief Executive Officer November 13, 2025 Buy 216,212 $3.25 $702,689
Brust Bernd Chief Executive Officer November 12, 2025 Buy 93,358 $3.21 $299,679
Brust Bernd Chief Executive Officer November 11, 2025 Buy 157,201 $3.24 $509,331

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 1 trade and filings

No trades in Maravai Lifesciences Holdings, Inc. disclosed in the last 12 months; 1 earlier trade on record.

  • Daniel S. Goldman(D-NY 10):Sale (full), $1,001 - $15,000, traded April 10, 2023, filed May 19, 2023

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 7, 2026
  • February 25, 2026
  • November 6, 2025
  • August 11, 2025
  • May 12, 2025

Recent SEC filings

Data status

When each part of this page on Maravai Lifesciences Holdings, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Maravai Lifesciences Holdings, Inc. in brief

What does Maravai Lifesciences Holdings, Inc. do?
Maravai Lifesciences Holdings, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is Maravai Lifesciences Holdings, Inc.'s stock ticker?
Maravai Lifesciences Holdings, Inc. trades under the ticker MRVI on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Maravai Lifesciences Holdings, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Maravai Lifesciences Holdings, Inc. reported revenue of $209M, 5.0% lower than a year earlier, according to its SEC filings.
What is Maravai Lifesciences Holdings, Inc.'s free cash flow?
Maravai Lifesciences Holdings, Inc.'s free-cash-flow margin is -17.2% of revenue over the trailing twelve months, ranking 37 of the 54 life sciences tools & services companies we cover.
Who are Maravai Lifesciences Holdings, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Gtcr LLC, Blackrock, Inc. and Braidwell LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Maravai Lifesciences Holdings, Inc.'s market cap?
On November 2, 2026, Maravai Lifesciences Holdings, Inc.'s market capitalisation was about $1.1B and net debt of $79.9M. Market figures come from third-party market data and may be delayed.
How much debt does Maravai Lifesciences Holdings, Inc. have?
Maravai Lifesciences Holdings, Inc.'s debt-to-equity ratio is 71.9%, from its latest balance sheet (166.3% five years earlier). The financial health section below sets out its other solvency checks.
Who are Maravai Lifesciences Holdings, Inc.'s competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Maravai Lifesciences Holdings, Inc. are Cytek Biosciences, Inc., Cryoport, Inc., Mesa Laboratories Inc, Schrodinger, Inc. and Grail, Inc. The side-by-side comparison below sets their revenue, margins and growth against Maravai Lifesciences Holdings, Inc.'s.
Are insiders buying or selling Maravai Lifesciences Holdings, Inc. stock?
Over the last 12 months, Maravai Lifesciences Holdings, Inc.'s directors and officers reported 5 open-market purchases and 2 sales on Form 4. The insider trading page charts every trade.
When is Maravai Lifesciences Holdings, Inc.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Maravai Lifesciences Holdings, Inc. announces its own schedule.